Last checked at 
Syncona Ltd - investor in life science companies - Portfolio firm Achilles Therapeutics PLC files with US Securities & Exchange Commission for a proposed initial public offering of American Depositary Shares. JP Morgan, BofA Securities and Piper Sandler are expected to be book-running managers for the IPO, with Chardan, Oppenheimer & Co and Kempen & Co as co-managers. Syncona says the number ADSs to be sold and the pricing have not yet been set. Achilles is a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumours.
Current stock price: 254.38 pence
Year-to-date change: down 2.5%
By Tom Waite; thomaslwaite@alliancenews.com
Copyright 2021 Alliance News Limited. All Rights Reserved.
